Abstract
Among 275 patients with COVID-19, we found that median blood zinc level was significantly lower in patients with poor clinical outcome (N = 75) as compared to patients with good clinical outcome (N = 200) (840 μg/L versus 970 μg/L; p < 0.0001), suggesting that zinc supplementation could be useful for patients with severe COVID-19.
Keywords: Azithromycin; Chloroquine; Clinical outcome; SARS-COV-2; Severe; Zinc.
All Keywords
【저자키워드】 SARS-CoV-2, Zinc, Chloroquine, Azithromycin, severe, Clinical outcome, 【초록키워드】 Zinc, Chloroquine, Azithromycin, severe COVID-19, severe, Clinical outcome, clinical, Patient, Blood, zinc supplementation, significantly lower, median, patients with COVID-19, 【제목키워드】 COVID-19, Patient, Blood, Concentration,
【저자키워드】 SARS-CoV-2, Zinc, Chloroquine, Azithromycin, severe, Clinical outcome, 【초록키워드】 Zinc, Chloroquine, Azithromycin, severe COVID-19, severe, Clinical outcome, clinical, Patient, Blood, zinc supplementation, significantly lower, median, patients with COVID-19, 【제목키워드】 COVID-19, Patient, Blood, Concentration,
{{{ 추상적인 }}}
COVID-19 환자 275명 중, 우리는 임상 결과가 좋은 환자(N = 200)(840μg/L 대 970μg)에 비해 임상 결과가 좋지 않은 환자(N = 75)에서 혈중 아연 수치 중앙값이 유의하게 낮음을 발견했습니다. /L; p < 0.0001), 아연 보충제가 중증 COVID-19 환자에게 유용할 수 있음을 시사합니다.
{{ 키워드: }} 아지트로마이신; 클로로퀸; 임상 결과; 사스 코로나바이러스 2; 중증; 아연.